QPPV.COM KNOWLEDGE ASSESSMENT

Cariprazine: Discovery, Development, Safety and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Cariprazine: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why is a lack of improvement 48 hours after cariprazine discontinuation generally insufficient to exclude a drug contribution to a suspected adverse reaction?
Question 2 of 10 Which conclusion is best supported by the 26-week cariprazine-versus-risperidone trial in adults with predominant negative symptoms?
Question 3 of 10 Which stratification approach is most appropriate when evaluating a potential cariprazine safety signal?
Question 4 of 10 Which interpretation best describes the pharmacological significance of cariprazine being a D3/D2 partial agonist?
Question 5 of 10 A patient taking an antipsychotic develops fever, rigidity, altered mental state and autonomic disturbance. What is the most appropriate pharmacovigilance and clinical interpretation?
Question 6 of 10 A colleague proposes estimating global cariprazine sales by treating one company's reported product revenue as total INN revenue. Which response best reflects the article's commercialisation discussion?
Question 7 of 10 What is the most balanced interpretation of the bipolar-depression phase 3 results described in the article?
Question 8 of 10 Which statement correctly distinguishes seriousness, causality, listedness and expectedness in a safety assessment?
Question 9 of 10 A reviewer finds Stevens–Johnson syndrome in the assessed US Vraylar postmarketing section but does not find it named in the reviewed EU Reagila hard-capsule section 4.8 table. Which conclusion is most defensible?
Question 10 of 10 What is the most appropriate interpretation of the cariprazine relapse-prevention study that first stabilised patients on open-label treatment and then randomised them to continue treatment or receive placebo?

Select an answer to continue.

QPPV.com